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Abstract
• Evidence shows that bacterial vaginosis (BV) can lead to poor
perinatal outcomes.
• The goal of this project is to answer the question of which
pregnant patients should be screened for BV and does
identification and treatment of BV during pregnancy improve
perinatal outcomes.
• Due to variability in a multitude of factors, a generalized
recommendation is difficult to make. Lack of recommendations
are largely due to harm of treatment in those who were
misdiagnosed.
• The development of polymerase chain reaction (PCR) has the
capability to reduce misdiagnosis.
• Newer studies have shown benefit of early screening and
treatment and the use of clindamycin over the traditional
treatment of metronidazole.
• An online search of PubMed, CINHAL, and Cochrane databases
in the past 10 years yielded meta-analyses, systematic reviews,
random control trials, and cohort studies. Additional sources found
using reference lists. Search terms utilized included; bacterial
vaginosis, vaginitis, pregnancy, pregnant, miscarriage, screening,
pre-term, and asymptomatic.

Literature Review

Discussion

• The 2008 USPSTF and 2015 CDC guidelines recommend
against routine screening of pregnant women for BV based on
lack of consistent benefit and possible risk of harm.
• Historically, diagnosis is made by Amsel or Nugent criteria.
• Intermediate flora; Nugent score of 4-6 has also been associated
with poor perinatal outcomes.
• SOGC guidelines states vaginal therapy is not recommended for
the indication of preventing adverse pregnancy outcomes.
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Incidence rate of bacterial vaginosis and

• The consensus remains against a screening and treatment
protocol for all pregnant women.
• Of the treatment trials used for the USPSTF recommendations,
one found asymptomatic women who were treated with
metronidazole had increased risk of preterm delivery.
• The other treatment trials used for USPSTF recommendations,
found no statistically significant adverse effects to pregnancy
outcomes.
• “Vaginal contents are in communication with the uterus until the
fusion of the decidua capsularis with the decidua paretalis at 1416 weeks of gestation". (Koumans et al. 2011, p. 1021)
• Many of the current studies used to make recommendations
involve screening that took place after 14-16 weeks gestation.
• BV appears to have a higher incidence among women with
infertility and is associated with preclinical pregnancy loss.
• Risk factors for BV include; history of miscarriage, PTD, or
infertility. Age < 30, African American race, recent history or
current smoker, increased number of sexual partners, history of
STDs, douching, high school level of education or less.
• Alteration in vaginal flora increases risk for acquiring other
sexually transmitted diseases.

Applicability to Practice
• USPSTF guidelines are currently under revision.
• BV can now be diagnosed using polymerase chain reaction
(PCR). It is predicted to have a sensitivity of 100% and specificity
of 93%.
• Much of the research does not include if other infections were
present at the time of diagnosis or if the patients have had history
of vaginitis or STDs.
• It appears Candida, Trichomonas, and other STDs can play a role
in miscarriage and can also contribute to the patient being
asymptomatic to a BV infection.
• Further studies are needed that focus on using PCR for diagnosis,
early screening; prior to the closure of the decidua, and
clindamycin for treatment.
• Screening may also be beneficial for those struggling with
preclinical miscarriage.
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Introduction
• BV occurs when there is a disruption of the normal flora;
Lactobacilli and an overgrowth of anaerobic bacteria.
• Chorioamnionitis, preterm delivery (PTD), preterm rupture of
membranes (PROM), and miscarriage have all been associated
with positive bacterial vaginosis during pregnancy.
• BV is present in 20-50% of women during pregnancy and most
cases are asymptomatic.
• Up to 50% of BV cases clear without treatment but others may
recur after treatment.
• Alteration in vaginal flora increases risk of acquiring other STDs
• First line treatment for BV positive pregnant women is oral
metronidazole or clindamycin.
• Clindamycin has a broader range against atypical mycoplasma
and Mobiluncus compared to the traditional treatment of
metronidazole.

• Koumans et al found no statistical significance for preterm
delivery between women treated for abnormal flora or BV vs
women with normal flora.

Screening & treatment of asymptotic BV,
Candidiasis, & Trichomonas

•

• A retrospective study done by McNamee et al found
chorioamnionitis in 94% of preterm deliveries (PTD) prior to 24
weeks gestation.

•

• According to Nelson et al, there is a relationship between
asymptomatic BV and less stress, history of STDs, & higher
quantity of Mobiluncus.
• Usher-Pines et al found lower levels of Lactobacillus were
associated with African American race and douching.

•

o Higher amounts of Mobiluncus & Gardneralla were correlated
with African American race, single women, & smokers.
• A meta-analysis by Van Oostrum et al found a higher incidence
of abnormal flora and BV among infertility patients & an
association between BV and preclinical pregnancy loss (p<0.01).
Treatment of bacterial vaginosis and effect

•

•
•

Number of spontaneous PTD < 37 weeks.
(p=0.0001)
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•

on perinatal outcomes

Statement of the Problem
• BV is the most common lower genital tract syndrome in women of
reproductive age and research has shown that it is linked to poor
perinatal outcomes. There are varying opinions on which pregnant
patients should be screened for BV and what treatments should
be used.

Research Question
• Would screening and treatment for asymptomatic BV improve
perinatal outcomes?

• A Cochrane review of BV positive women done by Brocklehurst
et al found treatment with clindamycin reduced the incidence of
late miscarriage. PTBs <37 weeks were reduced when
intermediate flora was treated with clindamycin.
• Haahr et al made a strong recommendation against treatment for
BV positive women using metronidazole to reduce risk of PTD. If
clindamycin was started before 20 weeks gestation there was a
slight reduction in pPROM.
• Lamont et al found oral clindamycin had a 61% reduction in PTD
<37 weeks and a 27% reduction with clindamycin vaginal cream.
• Workowskit & Bolan recommend treatment for all symptomatic
patients. Treatment of asymptomatic high risk patients may be
beneficial. Treatment of asymptomatic low risk patients remains
unclear.
• A Cochrane review done by Sangkomkamhang et al showed
screening and treatment for antenatal lower genital infections
reduces preterm birth.
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